Evidence map›Paper›PMID 27381684›Full record

ReviewImmunotherapy2016

IFN-λ cancer immunotherapy: new kid on the block.

Ahmed Lasfar, Helen Gogas, Andrew Zloza, Howard L Kaufman, John M Kirkwood

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Engineering adoptive cell therapy for solid tumors.Medical oncology (Northwood, London, England) · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ahmed LasfarDepartment of Pharmacology & Toxicology, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ 08854, USA.
Helen GogasFirst Department of Medicine, Medical School, University of Athens, Athens, Greece.
Andrew ZlozaDepartment of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, NJ, USA.
Howard L KaufmanDepartment of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, NJ, USA.
John M KirkwoodDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, PA, USA.

Funding

Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9M
NCI NIH HHS P50 CA121973
6 · The paper itself

Abstract

Interferon-lambda (IFN-λ) is a new IFN type, related to IFN-α, that is commonly used in the clinic. However, significant side effects accompanying IFN-α treatment limit enthusiasm for IFN-α. In this review, we discuss the current landscape of IFN-α use in oncology and describe the biologic characteristics of IFN-λ. IFN-λ offers unique advantages, including a more tumor cell selective targeting, lower off-target binding and an ability to generate both innate and adaptive immune responses. IFN-λ has also demonstrated therapeutic benefit in murine cancer models. IFN-λ may be used in clinic as a single agent or in combination with other immunotherapy agents, such as immune checkpoint inhibitors. Further clinical trials will be needed to fully elucidate the potential of this novel agent in oncology.

Indexed as

Adaptive ImmunityAnimalsAntineoplastic AgentsCostimulatory and Inhibitory T-Cell ReceptorsDisease Models, AnimalDrug Therapy, CombinationHumansImmunity, InnateImmunotherapyInterferon LambdaInterferonsInterleukinsMiceNeoplasmsAntineoplastic AgentsCostimulatory and Inhibitory T-Cell ReceptorsIFNL4 protein, humanInterferon Lambdainterferon-lambda, humanInterferonsInterleukinsIFN therapyIFN-α/λ combinationIFN-λimmune check point inhibitors

Identifiers

PMID27381684
PMCPMC5619162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.